胶质瘤治疗的新兴前沿：胶质瘤疫苗不断演变的作用

摘要(中文译文)

胶质瘤，尤其是胶质母细胞瘤（GBM），仍是最致命的原发性脑肿瘤之一，其特征为侵袭性生物学行为、显著的瘤内异质性以及高度免疫抑制的肿瘤微环境。尽管癌症免疫治疗取得了令人鼓舞的进展，但胶质瘤疫苗所带来的持久临床获益仍然有限，凸显了早期免疫原性与长期治疗疗效之间存在显著的转化鸿沟。在本综述中，我们对当前胶质瘤疫苗策略进行了整合性概述，包括基于多肽、基于树突状细胞、基于核酸以及自体肿瘤来源的平台，并特别关注其生物学依据、临床表现及转化局限性。我们不仅总结近期进展，还批判性地审视了制约临床成功的共同因素，包括抗原异质性、免疫逃逸、HLA限制、治疗相关免疫抑制以及胶质瘤肿瘤微环境的抑制作用。我们进一步讨论了这些挑战如何塑造了将疫苗与化疗、抗血管生成药物、免疫检查点阻断及其他免疫治疗手段联合应用的新兴理论基础。最后，我们重点阐述了下一代胶质瘤疫苗的前瞻性设计原则，包括改进抗原选择、生物标志物指导的患者分层、微环境感知的治疗设计以及更具预测性的转化模型。总体而言，我们提出，胶质瘤疫苗治疗的未来进展不仅取决于疫苗平台本身的改进，还取决于将其整合到生物学合理且具有临床依据的治疗框架中。

Abstract

Glioma, particularly glioblastoma (GBM), remains one of the most lethal primary brain tumors, characterized by aggressive biological behavior, profound intratumoral heterogeneity, and a highly immunosuppressive tumor microenvironment. Despite encouraging advances in cancer immunotherapy, durable clinical benefit from glioma vaccines has remained limited, highlighting a substantial translational gap between early immunogenicity and long-term therapeutic efficacy. In this review, we provide an integrative overview of current glioma vaccine strategies, including peptide-based, dendritic cell-based, nucleic acid-based, and autologous tumor-derived platforms, with a particular focus on their biological rationale, clinical performance, and translational limitations. Rather than merely summarizing recent developments, we critically examine the shared factors that have constrained clinical success, including antigen heterogeneity, immune escape, HLA restriction, treatment-related immunosuppression, and the inhibitory effects of the glioma tumor microenvironment. We further discuss how these challenges have shaped the emerging rationale for combination strategies involving vaccines with chemotherapy, anti-angiogenic agents, immune checkpoint blockade, and other immunotherapeutic modalities. Finally, we highlight forward-looking design principles for next-generation glioma vaccines, including improved antigen selection, biomarker-guided patient stratification, microenvironment-aware therapeutic design, and more predictive translational models. Overall, we propose that future progress in glioma vaccine therapy will depend not only on improving vaccine platforms themselves, but also on integrating them into biologically rational and clinically informed therapeutic frameworks.

如何引用

Frontiers in immunology 的其他文献

• 探索肠道-代谢物-免疫轴：增强免疫检查点抑制剂的疗效并减轻毒性
• 牙周炎与种植体周围炎的多组学比较揭示了浆细胞富集是两者共同特征，以及牙周炎相关的内皮-浆细胞APP-CD74轴
• 铁下垂：牙周炎的一个有前景的治疗靶点
• 睡眠和昼夜节律紊乱重塑口腔组织的免疫稳态：褪黑素和皮质醇在牙周病和口干症中的机制作用
• 释放工程外泌体用于膝骨性关节炎治疗的潜力
• 基孔肯雅甲型病毒的先天免疫感应：平衡抗病毒防御和发病机制
• 癌症中的PRMT3：精氨酸甲基化作为肿瘤代谢、免疫逃避和治疗耐药性的驱动因素
• 针对相关慢性肝脏炎症的多表位疫苗候选物的计算机模拟设计与实验验证。{"i":["幽门螺杆菌"]}
• 中枢神经系统疾病中的铁中毒免疫串扰：机制和翻译见解
• NLRP3炎性体在脓毒症“免疫麻痹过度激活”失衡中的调节机制：从分子信号传导到临床翻译的最新进展